Regularly updated material to support the introduction of adalimumab, eculizumab, natalizumab, ranibizumab and tocilizumab biosimilars.

Understand the area

Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions

Resources to support the choice of adalimumab biosimilar within organisations.

Understand the adalimumab products that are available on contract to the NHS. Choose between them appropriately for organisations or individuals.

Eculizumab

Resources to support the choice of eculizumab biosimilar within organisations.

Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.

Natalizumab

Resources to support the choice of natalizumab biosimilar within organisations.

Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.

Ranibizumab for ocular use

Resources to specifically support the introduction of ranibizumab biosimilar for ocular use.

Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
Three licensed ranibizumab biosimilars are available: Byooviz, Ongavia and Ximluci. Learn about the licensed indications and supporting evidence

Tocilizumab

Resources to support the choice of tocilizumab biosimilar within organisations.

Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.